Merdan Thomas, Kunath Klaus, Petersen Holger, Bakowsky Udo, Voigt Karl Heinz, Kopecek Jindrich, Kissel Thomas
Department of Pharmaceutics and Biopharmacy, Philipps-University of Marburg, Ketzerbach 63 , D-35032 Marburg, Germany.
Bioconjug Chem. 2005 Jul-Aug;16(4):785-92. doi: 10.1021/bc049743q.
The influence of PEGylation on polyplex stability from poly(ethylene imine), PEI, and plasmid DNA was investigated both in vitro and after intravenous administration in mice. Polyplexes were characterized with respect to particle size (dynamic light scattering), zeta-potential (laser Doppler anemometry), and morphology (atomic force microscopy). Pharmacokinetics and organ accumulation of both polymers and pDNA were investigated using 125I and 32P radioactive labels, respectively. Furthermore gene expression patterns after 48 h were measured in mice. To elucidate the effect of different doses, all experiments were performed using ca. 1.5 microg and 25 microg of pDNA per mouse. Our studies demonstrated that both PEI and PEG-PEI form stable polyplexes with DNA with similar sizes of 100-130 nm. The zeta potential of PEI/pDNA polyplexes was highly positive, whereas PEG-PEI/pDNA showed a neutral surface charge as expected. The pharmacokinetic and organ distribution profiles after 2 h show similarities for both PEI and pDNA blood-level time curves from polyplexes at both doses indicative for significant stability in the bloodstream. A very rapid clearance from the bloodstream was observed and as major organs of accumulation liver and spleen were identified. PEG-PEI/pDNA complexes at a dose of approximately 25 microg exhibit similar profiles except a significantly lower deposition in the lung. At the lower dose of approximately 1.5 microg pDNA, however, for polyplexes from PEG-PEI, significant differences in blood level curves and organ accumulation of polymer and pDNA were found. In this case PEG-PEI shows a greatly enhanced circulation time in the bloodstream. By contrast, pDNA was rapidly cleared from circulation and significant amounts of radioactivity were found in the urine, suggesting a rapid degradation possibly by serum nucleases after complex separation. Regarding in vivo gene expression, no luciferase expression could be detected at approximately 1.5 microg dose in any organ using both types of complexes. At 25 microg only in the case of PEI/pDNA complexes were significant levels of the reporter gene detected in lung, liver, and spleen. This coincided with high initial accumulation of pDNA complexed with PEI and a high acute in vivo toxicity. For PEG-PEI, initial accumulation was much lower and no gene expression as well as a low acute toxicity was found. In summary, our data demonstrate that PEG-PEI used in this study is not suitable for low dose gene delivery. At a higher dose of approximately 25 microg, however, polyplex stability is similar to PEI/pDNA combined with a more favorable organ deposition and significantly lower acute in vivo toxicity. These findings have consequences for the design of PEG-PEI-based gene delivery systems for in vivo application.
研究了聚乙二醇化对聚乙烯亚胺(PEI)与质粒DNA形成的多聚体稳定性的影响,包括体外实验以及在小鼠体内静脉注射后的情况。通过动态光散射表征多聚体的粒径,激光多普勒测速法测定其zeta电位,原子力显微镜观察其形态。分别使用125I和32P放射性标记研究了聚合物和质粒DNA的药代动力学及器官蓄积情况。此外,还测定了小鼠在48小时后的基因表达模式。为阐明不同剂量的影响,所有实验均使用每只小鼠约1.5μg和25μg的质粒DNA进行。我们的研究表明,PEI和聚乙二醇化聚乙烯亚胺(PEG-PEI)均能与DNA形成稳定的多聚体,其粒径相似,在100 - 130nm之间。PEI/DNA多聚体的zeta电位呈强阳性,而PEG-PEI/DNA如预期显示出中性表面电荷。2小时后的药代动力学和器官分布情况表明,两种剂量下PEI和DNA从多聚体中的血药浓度-时间曲线相似,这表明它们在血液中具有显著的稳定性。观察到从血液中的快速清除,并确定肝脏和脾脏为主要蓄积器官。剂量约为25μg的PEG-PEI/DNA复合物表现出相似的分布情况,只是在肺中的沉积明显较低。然而,在较低剂量约1.5μg质粒DNA时,PEG-PEI形成的多聚体在血药浓度曲线以及聚合物和DNA的器官蓄积方面存在显著差异。在这种情况下,PEG-PEI在血液中的循环时间大大延长。相比之下,质粒DNA迅速从循环中清除,尿液中发现大量放射性,这表明复合物分离后可能被血清核酸酶迅速降解。关于体内基因表达,使用两种类型的复合物在约1.5μg剂量下,任何器官均未检测到荧光素酶表达。在25μg剂量时,仅在PEI/DNA复合物的情况下,在肺、肝脏和脾脏中检测到显著水平的报告基因。这与与PEI复合的质粒DNA的高初始蓄积以及高急性体内毒性相一致。对于PEG-PEI,初始蓄积要低得多,未发现基因表达且急性毒性较低。总之,我们的数据表明,本研究中使用的PEG-PEI不适用于低剂量基因递送。然而,在约25μg的较高剂量下,多聚体稳定性与PEI/DNA相似,同时具有更有利的器官沉积和显著更低的急性体内毒性。这些发现对基于PEG-PEI的体内基因递送系统的设计具有重要意义。